Amgen: Jefferies maintains buy rating after new data

(CercleFinance.com) - On Monday an analyst at Jefferies confirms a "buy" rating on the Amgen stock, after the group yesterday announced positive results for its drug AMG-510 in the treatment of a form of lung cancer.


"We think that this likely sets up for a short-term trading dynamic... We continue to believe the drug will move toward FDA approval over the next 1-2 years," the broker says.

Jefferies confirms its target price of 235 dollars for the stock.


Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.